TY  - BOOK
AU  - Haffajee, Rebecca L.
AU  - Mikos, Robert A. 
AU  - Cooper, Ziva D. 
TI  - Marijuana Rescheduling — A Game Changer for Research?
KW  -  MEDICAMENTOS, DISPOSITIVOS Y LA FDA
KW  - HEMATOLOGÍA
KW  - ONCOLOGÍA GENERAL
KW  - DOLOR
KW  - TRATAMIENTOS EN ONCOLOGÍA
KW  - DERECHO SANITARIO
N2  - On April 22, 2026, the U.S. acting attorney general issued a final rule immediately reclassifying state-licensed medical marijuana products and future Food and Drug Administration (FDA)–approved marijuana products under Schedule III of the Controlled Substances Act. Medical marijuana (cannabis containing ≥0.3% tetrahydrocannabinol), now legal in 40 states, three territories, and the District of Columbia, was previously federally designated as a Schedule I drug — the category of drugs that are the most tightly controlled
ER  -